BSX Boston Scientific Corp

Price (delayed)

$42.66

Market cap

$60.79B

P/E Ratio

55.4

Dividend/share

N/A

EPS

$0.77

Enterprise value

$67.93B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, ...

Highlights
The P/E is 38% below the 5-year quarterly average of 88.9
Boston Scientific's gross profit has increased by 14% YoY and by 3.2% QoQ
The EPS has soared by 108% from the previous quarter but it has plunged by 71% YoY
Boston Scientific's net income has surged by 99% QoQ but it has shrunk by 69% YoY
BSX's quick ratio is down by 18% year-on-year and by 16% since the previous quarter

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.42B
Market cap
$60.79B
Enterprise value
$67.93B
Valuations
Price to earnings (P/E)
55.4
Price to book (P/B)
3.69
Price to sales (P/S)
5.3
EV/EBIT
42.11
EV/EBITDA
19.19
EV/Sales
5.92
Earnings
Revenue
$11.47B
EBIT
$1.61B
EBITDA
$3.54B
Free cash flow
$1.72B
Per share
EPS
$0.77
Free cash flow per share
$1.21
Book value per share
$11.56
Revenue per share
$8.06
TBVPS
$9.71
Balance sheet
Total assets
$31.88B
Total liabilities
$15.42B
Debt
$9.09B
Equity
$16.46B
Working capital
$2.21B
Liquidity
Debt to equity
0.55
Current ratio
1.55
Quick ratio
0.9
Net debt/EBITDA
2.02
Margins
EBITDA margin
30.9%
Gross margin
67.4%
Net margin
10.1%
Operating margin
8.9%
Efficiency
Return on assets
3.5%
Return on equity
6.9%
Return on invested capital
9.2%
Return on capital employed
5.8%
Return on sales
14.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
-0.72%
1 week
-4.9%
1 month
-0.14%
1 year
15.2%
YTD
0.42%
QTD
0.42%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$11.47B
Gross profit
$7.73B
Operating income
$1.02B
Net income
$1.16B
Gross margin
67.4%
Net margin
10.1%
Boston Scientific's operating income has soared by 118% from the previous quarter
BSX's operating margin has surged by 112% since the previous quarter
Boston Scientific's net income has surged by 99% QoQ but it has shrunk by 69% YoY
Boston Scientific's net margin has surged by 94% QoQ but it has shrunk by 72% YoY

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
P/E
55.4
P/B
3.69
P/S
5.3
EV/EBIT
42.11
EV/EBITDA
19.19
EV/Sales
5.92
The EPS has soared by 108% from the previous quarter but it has plunged by 71% YoY
The P/E is 38% below the 5-year quarterly average of 88.9
The stock's price to book (P/B) is 21% less than its 5-year quarterly average of 4.7 but 2.5% more than its last 4 quarters average of 3.6
The equity has grown by 6% YoY and by 3.3% from the previous quarter
The revenue has increased by 13% YoY and by 2.4% from the previous quarter
BSX's P/S is 6% above its 5-year quarterly average of 5.0

Efficiency

How efficient is Boston Scientific business performance
The return on assets has surged by 106% since the previous quarter but it has dropped by 71% year-on-year
The return on equity has surged by 103% since the previous quarter but it has dropped by 72% year-on-year
BSX's ROIC has soared by 80% from the previous quarter
The ROS has soared by 74% from the previous quarter

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 107% more than its total liabilities
BSX's quick ratio is down by 18% year-on-year and by 16% since the previous quarter
BSX's current ratio is down by 17% year-on-year and by 7% since the previous quarter
Boston Scientific's debt is 45% lower than its equity
Boston Scientific's debt to equity has decreased by 8% YoY and by 3.5% from the previous quarter
The equity has grown by 6% YoY and by 3.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.